# Atossa Therapeutics, Inc. (ATOS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ATOS
## Company Profile
- Ticker: ATOS
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Oncology
## Stock Data
- Close: 2.53 USD
- Market cap: 41765100.849999994 USD
- Last updated: 2026-09-03
## Business Overview
Atossa Therapeutics is a breast-cancer company focused on therapies and diagnostics in oncology and women’s health. Its business is centered on targeted disease biology and cancer-related development.
## Why The Stock Is Moving

As of Sep 3, 2026, ATOS closed up 2.85% at $2.53. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Atossa sits in specialty oncology biotechnology.

## Business Model

The company depends on clinical data, biomarker strategy, and the ability to create a focused breast-cancer story.

## Landscape Position

Atossa is a catalyst-sensitive oncology name whose valuation is driven by data and differentiation.

## Future Catalysts

- Atossa’s catalysts are endoxifen and any breast-cancer development progress that keeps the selective-estrogen-receptor story alive. The next update matters because the company still needs stronger human evidence.

## Recent News
- 2025-09-17 12:00 EST — [Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations-shareholder-communic-7dbf6e27) — Source: Atossa Therapeutics, Inc.
- 2025-04-30 12:45 EST — [Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-281-056-including-58--540af8e3) — Source: Atossa Therapeutics, Inc.
- 2025-04-29 12:45 EST — [Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-proposes-potentially-groundbreaking-study-aimed-at-reducing--15eb7318) — Source: Atossa Therapeutics, Inc.
- 2025-04-22 12:45 EST — [Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-275-684-further-stren-7031edc2) — Source: Atossa Therapeutics, Inc.
- 2025-03-25 12:00 EST — [Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-full-year-2024-financial-results-and-provides-corp-d35fa88f) — Source: Atossa Therapeutics, Inc.